GNH USA

Europe — EMA

Ikatibant Fresenius (Icatibant Acetate)

GNH USA supplies Ikatibant Fresenius (Icatibant Acetate), a bradykinin B2 receptor antagonist for acute hereditary angioedema attacks.

Icatibant Acetate

Request sourcing

1
Pack/s

What is Icatibant Acetate?

Icatibant Acetate, the active ingredient in Ikatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with a confirmed diagnosis.

GNH USA supplies Ikatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Icatibant Acetate used for?

Icatibant Acetate is used to manage bradykinin‑mediated swelling disorders, particularly hereditary angioedema. - Hereditary angioedema (HAE) type I and II: Reduces swelling and shortens the duration of acute attacks. - Acute bradykinin‑mediated angioedema: Provides rapid symptom relief during sudden episodes. - HAE with C1‑esterase inhibitor deficiency: Restores normal vascular permeability during crises.

What are the side effects of Icatibant Acetate?

Icatibant Acetate may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: Discomfort at the site of subcutaneous administration. - Redness or erythema: Localized skin irritation. - Swelling at injection site: Mild to moderate edema. - Nausea: Transient gastrointestinal upset. - Headache: Mild to moderate intensity. - Dizziness: Transient sensation of light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: Rash, itching, or hives. - Anaphylaxis: Severe, potentially life‑threatening allergic response. - Severe hypotension: Marked drop in blood pressure. - Angioedema unrelated to HAE: Unexpected swelling in other areas. - Thrombocytopenia: Low platelet count. - Injection‑site infection: Signs of local infection such as warmth or pus.

What precautions apply to Icatibant Acetate?

Before using Icatibant Acetate, consider the following safety measures. - Renal impairment: Monitor renal function and adjust therapy as needed. - Hepatic impairment: Use with caution and observe liver function tests. - Pregnancy: Safety not established; weigh potential benefits against risks. - Concomitant ACE inhibitors or ARBs: May increase bradykinin levels; monitor for angioedema. - Known hypersensitivity: Discontinue immediately if allergic reaction occurs. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

What does Icatibant Acetate interact with?

Icatibant Acetate can interact with other medications that influence the bradykinin pathway or cardiovascular system.

Major Interactions (Avoid): - ACE inhibitors: Heightened risk of angioedema. - Angiotensin receptor blockers (ARBs): May amplify bradykinin‑mediated effects. - Other bradykinin‑targeting agents: Additive blockade could cause unexpected reactions.

Moderate Interactions (Monitor Closely): - Diuretics: Observe blood pressure and electrolyte balance. - Antihistamines: May mask early signs of hypersensitivity. - NSAIDs: Monitor for increased swelling or pain at injection site.

Frequently asked questions

What is Ikatibant Fresenius used for?+
Ikatibant Fresenius contains icatibant acetate, which is indicated for the treatment of acute attacks of hereditary angioedema (HAE). It works by rapidly reducing swelling and pain associated with HAE episodes, providing relief for patients experiencing sudden, potentially life‑threatening swelling.
How does icatibant acetate work?+
Icatibant acetate is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin from causing vasodilation and increased vascular permeability, the key mechanisms that lead to the swelling seen in hereditary angioedema.
What is the usual dose of Ikatibant Fresenius?+
The dosing regimen for Ikatibant Fresenius is determined by the prescribing clinician based on the patient’s condition, severity of the attack, and individual response. Healthcare professionals follow approved guidelines to decide the appropriate amount and frequency of administration.
Is Ikatibant Fresenius safe during pregnancy or breastfeeding?+
Safety data for icatibant acetate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.
How do I order Ikatibant Fresenius from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.
How does Ikatibant Fresenius compare with other HAE treatments?+
Ikatibant Fresenius is a bradykinin B2 receptor antagonist, whereas alternative HAE therapies may include C1‑esterase inhibitor concentrates or kallikrein inhibitors. Icatibant offers a subcutaneous route and rapid onset, making it suitable for patients who prefer self‑administration and need quick symptom control.
What are the storage requirements for Ikatibant Fresenius?+
Ikatibant Fresenius should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.
How is Ikatibant Fresenius administered?+
The medication is given by subcutaneous injection, typically into the abdomen or thigh. A healthcare professional or trained patient can perform the injection using the supplied device, following aseptic technique and the dosing instructions provided by the prescriber.
What are the most serious risks associated with Ikatibant Fresenius?+
Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and rare cases of unexpected angioedema unrelated to HAE. Patients should be monitored closely after injection, and any signs of severe allergic reaction require immediate medical attention.
Who should not use Ikatibant Fresenius?+
Patients with known hypersensitivity to icatibant acetate or any of the excipients should avoid the product. Additionally, individuals receiving ACE inhibitors, ARBs, or other bradykinin‑modulating drugs should consult their physician, as the combination may increase the risk of angioedema.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Icatibant Acetate
Route
Subcutaneous Use
Manufacturer
Fresenius Kabi D.O.O.
Origin
EU

Related products

Icatibant

Icatibant

Icatibant Acetate

Fresenius Kabi Deutschland Gmbh
EU
Icatibant

Icatibant

Icatibant Acetate

Newbury Pharmaceuticals Ab
EU
Icatibant Adalvo

Icatibant Adalvo

Icatibant Acetate

Adalvo Limited
EU
Icatibant Auxilia

Icatibant Auxilia

Icatibant Acetate

Auxilia Pharma
EU